Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Baxter
Cerilliant
Farmers Insurance
Deloitte
Boehringer Ingelheim
Medtronic
McKinsey
AstraZeneca

Generated: July 21, 2018

DrugPatentWatch Database Preview

Ucb Inc Company Profile

« Back to Dashboard

Summary for Ucb Inc
International Patents:330
US Patents:15
Tradenames:27
Ingredients:22
NDAs:40
Drug Master File Entries: 1
Patent Litigation for Ucb Inc: See patent lawsuits for Ucb Inc

Drugs and US Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-001 Oct 28, 2008 RX Yes No ➤ Sign Up ➤ Sign Up
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-004 Oct 28, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up
Ucb Inc DEXACORT dexamethasone sodium phosphate AEROSOL;NASAL 014242-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Ucb Inc AMITRIPTYLINE HYDROCHLORIDE amitriptyline hydrochloride TABLET;ORAL 085864-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc UNIRETIC hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 020729-002 Jun 27, 1997 4,344,949 ➤ Sign Up
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-002 Nov 30, 1999 4,837,223 ➤ Sign Up
Ucb Inc TUSSIONEX PENNKINETIC chlorpheniramine polistirex; hydrocodone polistirex SUSPENSION, EXTENDED RELEASE;ORAL 019111-001 Dec 31, 1987 4,762,709 ➤ Sign Up
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-001 Jan 19, 2005 6,024,981 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for UCB INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Orally Disintegrating Tablets 0.25 mg, 0.5 mg, 1 mg and 2 mg ➤ Subscribe 2005-12-27
➤ Subscribe Tablets 7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg ➤ Subscribe 2004-01-15
➤ Subscribe Tablets 50 mg, 100 mg, 150 mg, and 200 mg ➤ Subscribe 2012-10-29
➤ Subscribe Extended-release Transdermal Film 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr ➤ Subscribe 2013-11-26
➤ Subscribe Tablets 1000 mg ➤ Subscribe 2007-01-24
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 2012-10-29
➤ Subscribe Extended-release Tablets 1000 mg ➤ Subscribe 2011-01-07
➤ Subscribe Injection 10 mg/mL, 20 mL ➤ Subscribe 2016-06-30

Non-Orange Book US Patents for Ucb Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,217,826 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
7,358,276 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses ➤ Sign Up
7,863,316 Extended release formulation of Levetiracetam ➤ Sign Up
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Ucb Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
24/2006 Austria ➤ Sign Up PRODUCT NAME: ROTIGOTINE
00028 Netherlands ➤ Sign Up PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
C001/2009 Ireland ➤ Sign Up SPC001/2009: 20091013, EXPIRES: 20220316
2016013,C1265862 Lithuania ➤ Sign Up PRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Fuji
Merck
UBS
Moodys
Fish and Richardson
Express Scripts
Citi
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.